Calquence (Acalabrutinib): The 2032-2036 Generic Opportunity Window

AstraZeneca's blockbuster oral Bruton's tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib, $3.0B+ in full-year 2024 global product revenue, surging 20% year-over-year) presents a well-defined long-range generic opportunity window. Its core composition-of-matter and drug substance patent, US 9,290,504 ('4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as Btk inhibitors'), anchors market exclusivity through July 11, 2032, alongside method of use patent US 10,239,883. Secondary crystalline Form I polymorph protection under US 9,796,721 extends statutory Orange Book coverage through July 1, 2036. The U.S. market remains 100% brand-only today, with zero generic acalabrutinib approved or commercially sold. Major Indian generic pharmaceutical manufacturers maintain active Paragraph IV ANDA filings challenging listed patents, including Alembic Pharmaceuticals, Sun Pharma, Zydus Lifesciences, MSN Laboratories, Cipla, and Dr. Reddy's Laboratories. The 2032 to 2036 timeframe defines the primary competitive window for generic market entry.